Xinyu Su

Mr. Xinyu Su

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
LZLianjun Zhao
Lianjun Zhao
YRYu Ren
Yu Ren
ZZzhang zhang
zhang zhang
KZKelin Zheng
Kelin Zheng
JWjiayu wang
jiayu wang
ZZZhengyun Zou
Zhengyun Zou
Background Previous studies have suggested the potential synergistic antitumor activity when combining immune checkpoint inhibitors with anti-angiogenic agents in various solid tumors. We aimed to assess the efficacy and safety of camrelizumab (a humanized programmed cell death-1 antibody) plus apatinib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor) for patients with advanced mucosal melanoma (MM), and explore-related biomarkers. Methods We conducted a single-center, open-label, single-arm, phase II study. Patients with unresectable or recurrent/metastatic MM received camrelizumab and apatinib. The primary endpoint was the confirmed objective response rate (ORR). Results Between April 2019 and June 2022, 32 patients were enrolled, with 50.0% previously received systemic therapy. Among 28 patients with evaluable response, the confirmed ORR was 42.9%, the disease control rate was 82.1%, and the median progression-free survival (PFS) was 8.05 months. The confirmed ORR was 42.9% (6/14) in both treatment-naïve and previously treated patients. Notably, treatment-naïve patients had a median PFS of 11.89 months, and those with prior treatment had a median PFS of 6.47 months. Grade 3 treatment-related adverse events were transaminase elevation, rash, hyperbilirubinemia, proteinuria, hypertension, thrombocytopenia, hand-foot syndrome and diarrhea. No treatment-related deaths were observed. Higher tumor mutation burden (TMB), increased T-cell receptor (TCR) diversity, and altered receptor tyrosine kinase (RTK)/RAS pathway correlated with better tumor response. Conclusion Camrelizumab plus apatinib provided promising antitumor activity with acceptable toxicity in patients with advanced MM. TMB, TCR diversity and RTK/RAS pathway genes were identified as potential predictive biomarkers and warrant further validation. Trial registration number Chinese Clinical Trial Registry, ChiCTR1900023277.

4 January 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
NWNandie Wu
Nandie Wu
RZRuizhe Zhao
Ruizhe Zhao
YHYing Huang
Ying Huang
XSXinyu Su
Xinyu Su
YZYaping Zhang
Yaping Zhang
BLBaorui Liu
Baorui Liu
The clinical significance of necroptosis in gastric cancer (GC) has yet to be fully elucidated. The purpose of our study was to identify a necroptosis-relevant gene and to establish a prediction model to estimate the prognosis and therapeutic potential in GC. Here, we explored the expression profile of 76 necroptosis-related genes in TCGA-STAD patients. A six-gene risk score prediction model was established via regression analysis of the least absolute shrinkage and selection operator (LASSO) and validated in a separate cohort. Patients were separated into low- or high-risk groups according to the median risk score. We then compared and analyzed the biological process characteristics of two risk groups. Additionally, cell-to-cell communications and metabolic activity were analyzed in a single-cell solution. The in vitro experiments were conducted to explore the biological functions and drug sensitivity of necroptosis-related genes in gastric cancer. Our results identified that compared with the low-risk group, the high-risk group was associated with a higher clinical stage or grade and a worse prognosis. In addition, the low-risk group had higher levels of immunity and immune cell infiltration. Necroptosis was triggered by the TNF pathway in myeloid cells and the glycolysis pathway was altered. Necroptosis-related genes modulated the cell function, including proliferation and migration in vitro. Furthermore, the potential drugs’ sensitivity was higher in the low-risk subgroup. These findings could facilitate a better understanding and improve the treatment potential and prognosis of GC patients.

1 June 2018 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
RHRongbo Han
Rongbo Han
JWJingsun Wei
Jingsun Wei
HZHonghong Zhang
Honghong Zhang
XSXinyu Su
Xinyu Su
XCXia Chu
Xia Chu
CJChen Jinfei
Chen Jinfei
Influence of TS (rs34743033) and RUNX1 (rs2014300) gene polymorphisms on survival outcomes of fluorouracil-based chemotherapy in Chinese advanced gastric cancer patients Rongbo Han,1â??3 Jingsun Wei,1 Honghong Zhang,1 Xinyu Su,1 Xia Chu,4 Yuetong Chen,1 Yang Gong,1 Xiujuan Wang,2 Junfeng Shi,1 Jinfei Chen1,5 1Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, Peopleâ??s Republic of China; 2Department of Oncology, Taixing Peopleâ??s Hospital, Taixing, Jiangsu,Peopleâ??s Republic of China; 3Clinical Research Center, Xuyi Peopleâ??s Hospital, Xuyi, Jiangsu, Peopleâ??s Republic of China; 4School of Medicine, Southeast University, Nanjing, Jiangsu, Peopleâ??s Republic of China; 5Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, Peopleâ??s Republic of China Background: This study aimed to explore the clinical correlation of single-nucleotide polymorphisms of thymidylate synthase (TS) and runt-related transcription factor 1 (RUNX1) in patients with postoperative stage II and III gastric cancer (GC).Patients and methods: Samples were obtained from 661 patients with postoperative stage II and III GC. TS (rs34743033) and RUNX1 (rs2014300) were genotyped in 261 patients who received postoperative basic platinum and fluorouracil chemotherapy regimens and 400 patients who did not accept chemotherapy. Results: TS (rs34743033) variant genotypes significantly prolonged the median overall survival (OS) time compared to the patients who only received adjuvant chemotherapy (HR 1.604, 95% CI 1.068â??2.410, p=0.021). Moreover, 3R/3R variant genotypes were demonstrated to have a positive effect on the OS of patients who received chemotherapy based on cisplatin (HR 1.754, 95% CI 1.041â??2.954, p=0.031) compared to oxaliplatin. A stratification analysis indicated that 2R/3R and 2R/2R variant genotypes were associated with inferior survival in GC patients with intestinal-type tumors, tumor less than 5 cm in size, and poorly differentiated tumors (p

1 January 2018 in Journal of Cancer
Verified
Journal Article
Open access
XSXinyu Su
Xinyu Su
YXYiqi Xue
Yiqi Xue
JWJingsun Wei
Jingsun Wei
XHXinying Huo
Xinying Huo
YGYang Gong
Yang Gong
CJChen Jinfei
Chen Jinfei
Signet ring cell gastric cancer (SRCGC) is a special type of gastric cancer with rapid progression and poor prognosis. However, few available SRCGC cell lines from Chinese patients can be used for research, the molecular mechanism of its growth and metastasis is still incompletely understood. In this study, we established and characterized a novel SRCGC cell line, gc-006-03.The cells showed a tendency to pile up without contact inhibition. G-band karyotypes of gc-006-03 were revealed hypotriploid with a modal chromosome number of 51. Immunohistochemistry analysis showed that the cells were positive for CEA, CK7, CDX2 and Ki-67(45%), and negative for CK20, TTF1and Li-cadherin. Flow cytometry analysis showed that gc-006-3 had 25% of CD44+ cells. The cells possessed strong clonality and high plating efficiency, and the doubling time was 36h. The cells grew vigorously for more than 100 passages in serial culture. Meanwhile, the cells showed a high rate of tumor formation. Tumors were observed in all of the nude mice (5/5) given injections of the cells. The metastatic capability of the cell line was found in zebrafish injected the cells. The results of whole genome sequencing revealed the unique genomic characteristics of gc-006-03. In summary, this new stable cell line may be useful in basic and clinical research on gastric signet ring cell carcinoma.

26 February 2020 in PeerJ
Verified
Journal Article
Open access
PDF file
KJKan Jiang
Kan Jiang
XZXiaohui Zhi
Xiaohui Zhi
YSYue Shen
Yue Shen
YMYuanyuan Ma
Yuanyuan Ma
XSXinyu Su
Xinyu Su
LZLiqing Zhou
Liqing Zhou
Purpose The relationship between examined lymph nodes (ELN) and survival has been confirmed in several single early-stage malignancies. We studied the association between the ELN count and the long-term survival of T1-2N0M0 double primary non-small cell lung cancer (DP-NSCLC) patients after surgery, based on the Surveillance, Epidemiology and End Results (SEER) database. Methods A total of 948 patients were identified and their independent prognostic factors were analyzed. These factors included the ELN count, which related to overall survival (OS) and the cancer-specific survival (CSS) of synchronous (n = 426) and metachronous (n = 522) T1-2N0M0 DP-NSCLC patients after surgery. Results X-tile analysis indicated that the cutoff value for the sum of ELNs was 22 for both OS and CSS in the synchronous DP-NSCLC group. Patients with a sum of ELNs >22 were statistically more likely to survive than those with ≤22 ELNs. X-tile analysis revealed that the ELN count of the second lesion was related to both OS and CSS in the metachronous DP-NSCLC group. The optimal cutoff value was nine. These results were confirmed using univariate and multivariate Cox regression analyses. Conclusion Our findings indicate that ELN count was highly correlated with the long-term survival of T1-2N0M0 double primary NSCLC patients after surgery.

15 July 2025 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
RHRong Huang
Rong Huang
XSXinyu Su
Xinyu Su
JWJiayu Wang
Jiayu Wang
QSQi Sun
Qi Sun
DKDonglin Kang
Donglin Kang
ZZZhengyun Zou
Zhengyun Zou
Background: Intratumoral fungi have recently been implicated in cancer initiation and progression, with potential as biomarkers for predicting clinical outcomes and treatment response in patients with cancer. However, their role in acral melanoma (AM) has not been previously explored. Methods: We characterized the mycobiome in AM tumor tissues and adjacent non-tumor tissues. Differences in fungal communities between the two tissues, as well as the prognostic and diagnostic potential of intratumoral fungi, and their associations with the tumor microenvironment and clinicopathologic features, were evaluated through bioinformatics and biostatistical analyses. Results: Although some intratumoral fungi originated from adjacent tissues, AM tumors exhibited a distinct fungal composition characterized by altered species richness, community structure, and an increased Ascomycota-to-Basidiomycota ratio. Several fungal taxa were identified as potential diagnostic and prognostic biomarkers and showed significant correlations with clinical parameters and immune infiltration. Specifically, the CD68-high samples harbored greater fungal diversity and higher relative abundance of Endocarpon compared with CD68-low samples. Furthermore, fungi–bacteria interactions were characterized by significant negative correlations between their diversity, while positive interspecies interactions dominated the network. Conclusions: These findings underscore the potential role of the cancer mycobiome in AM and offer new insights into the tumor microenvironment and its implications for cancer prevention and therapy.